Skip to main content
. 2022 May 24;11(11):1727. doi: 10.3390/cells11111727

Figure 4.

Figure 4

Radiosensitizing effects of LY2874455 in a nude mouse xenograft model. Mice received oral LY2874455 (3 mg/kg body weight) once daily for 7 consecutive days (i.e., Day 1–7). One hour after the first drug administration, tumors were irradiated with X-rays (10 Gy). (A) Immunoblots showing suppression of ERK phosphorylation by LY2874455. A549 tumor xenografts were resected from LY2874455-treated or -untreated mice 12 h after the second drug administration (n = 4 per group). pERK, phosphorylated ERK. The lower panel shows the quantitation of the immunoblots shown in the upper panel; the ratio of pERK to ERK is shown after normalizing to β-actin. ***, p < 0.001 (Mann–Whitney U-test). (B) Growth of A549 tumor xenografts (mean ± s.e.m., n = 6). ***, p < 0.001 (ANCOVA test, followed by a post-hoc pairwise comparison test). IR, X-rays (10 Gy); LY, LY2874455 (3 mg/kg body weight).